Cohort profile: pediatric patients with Crohn’s disease qualified to biologic therapy
Journal Title: Postępy Nauk Medycznych - Year 2014, Vol 27, Issue 3
Abstract
Introduction. Treatment with modern therapies is an economic problem in every country. Therefore, there are therapeutic programs of National Health Fund (NHF) in Poland which enable to apply such expensive treatment. Currently, Polish NHF programs include biologic therapy with infliximab (IFX) for pediatric patients aged 6-18 years with severe Crohn’s disease (CD).Aim. The aim of this study was to describe the clinical profile of pediatric patients hospitalized in the Department of Gastroenterology, Hepatology and Feeding Disorders, Children’s Memorial Health Institute in Warsaw, who have been qualified to biologic therapy with either infliximab (IFX) or adalimumab (ADA).Material and methods. We have performed a retrospective analysis of 107 children age 13.0 ± 9.3 years diagnosed with CD and treated with IFX and/or ADA within the period of 8 year; time between 2005 and 2013. The data on patient’s demographics, including age, sex, and age at disease onset as well as on the course and behavior of CD have been collected.Results. One hundred and seven CD patients (M: 54, F: 53) aged 13.0 ± 9.3 years were analyzed. Eighty one children (75.7%) received IFX, 26 (24.3%) ADA, and 8 (7.5%) were treated with both agents. Mean disease duration was 5.5 ± 0.83 years. The most frequently found location of lesions was L3 (56.1%). Extraintestinal manifestations were reported in 18 patients (16.8%), and arthralgia/arthritis was the most frequently found condition among them (77.8%). The most frequently found complication were nutritional and growth disorders, observed in 10 patients (9.3%). Mean PCDAI score at qualification was (median± ) 52.5]±27.5. Mean SES-SD (median [interquartile range]) score at qualification was 1 (1.0-22.0).Conclusions. Pediatric patients qualified to biologic therapy have rather severe than moderate course of disease with high PCDAI score.
Authors and Affiliations
Edyta Szymańska, Maciej Dądalski, Grzegorz Oracz, Jarosław Kierkuś
Keywords
Related Articles
- EP ID EP54923
- DOI -
- Views 143
- Downloads 0
Aktualne metody terapeutyczne u dzieci z kardiomiopatią przerostową – doświadczenia własne
Wstęp. Przebieg kliniczny kardiomiopatii przerostowej (HCM) u dzieci jest bardzo różnorodny. U niektórych dzieci, przerost mięśnia sercowego powoduje postępującą niewydolność serca i występowanie zagrażających życiu zabu...
Fibromialgia – choroba czy zespół bólowy?
Fibromialgia jest niezapalną chorobą z bólem, cechującą się uogólnionym bólem i rozlaną tkliwością. Głównymi objawami towarzyszącymi są: zmęczenie, zaburzenia snu, bóle głowy i zaburzenia pamięci. Przyczyna choroby jest...
Does statins increase the risk of liver damage?
Statins inhibit cholesterol biosynthesis, successfully prevent the coronary heart disease and rarely cause adverse effects. Higher risk of liver damage can be expected in elderly patients, with other systemic diseases, r...
Potential etiologic factors in patients with persistent pruritus ani
Introduction. Perianal pruritus is probably the most common cutaneous disorder of the genitoanal area. Studies on the epidemiology of causative factors are rare. It occurs in about 1-5% of the population, four times more...
Signs and symptoms of dehydration in the elderly
Evaluation of the hydration status is probably the most difficult task in clinical examination.The clinical and objective determinations of hydration status frequently differ. Theintracellular water volume remains stable...